GHK-Cu Dosage Guide: Injection Protocol & Dosage Chart [2026]

Understand what GHK-Cu dosing claims are based on, what topical human studies show, and how concentration differs from dose. Includes corrected syringe arithmetic and practical preparation questions.

Injectable GHK-Cu Dosage Overview

There is no established standard injection dose in the human evidence reviewed here. The earlier version of this page described 1–3 mg daily as a well-researched regimen and 2 mg as optimal. Those claims were not supported by a matching human dose-finding trial. They should not be used to choose a starting dose, maximum dose or escalation schedule.

GHK-Cu remains an interesting research compound. Human topical studies and laboratory formulation research address different questions from daily subcutaneous use. Reported experiences can suggest questions for research, but cannot establish how reliably injections work or which amount has the best benefit-to-risk balance.

Human topical evidence: a randomized diabetic neuropathic-ulcer study reported improved healing with a copper-peptide gel alongside debridement, pressure-relieving footwear and diabetes care. In a separate laser-resurfacing trial with 13 completers, patient satisfaction favored the GHK-Cu regimen, but objective between-group skin measures did not significantly improve. Neither establishes an injection protocol. Mulder et al., 1994; Miller et al., 2006.

GHK-Cu Dosage Chart: Beginner to Advanced

This chart preserves the questions behind the former beginner-to-advanced schedule while correcting its evidence status. These are earlier page claims, not recommended doses.

A research concentration, a vial label and a syringe marking answer different questions. None alone supplies a clinically validated dose.

Beginner Dosing Protocol: Safe Titration

The heading above reflects a common search question, not a validated safe-titration protocol. Starting with less may reduce exposure, but does not establish safety or rule out allergy, contamination or later adverse effects. We cannot substantiate the former promise of minimal side effects at 1 mg or an optimal benefit-to-risk ratio at 2 mg.

Before considering an injectable product, clarify its exact identity, concentration, intended route and dispensing instructions with the prescribing clinician and pharmacist. A topical cosmetic or research-use vial is not interchangeable with a preparation supplied for a patient. Do not derive a personal regimen from topical trials or from another person's report.

For a useful baseline, record the actual concern being treated, existing products and medications, and an objective way to assess change. Consistent photographs can document appearance, but lighting, concurrent treatment and natural recovery affect comparisons. A favorable before-and-after image is not a dose-finding study.

Intermediate & Advanced Dosing (2-3 mg Daily)

The 2–3 mg range in this heading is retained as correction context. The cited human research does not establish it as an intermediate or advanced injection regimen. Claims that 2.5 mg produces proportionally stronger benefits, or that 3 mg maximizes collagen production, require direct comparisons that are not supplied by this evidence.

Tolerating a product for a short period does not demonstrate that increasing it is beneficial, that indefinite use is safe, or that a higher dose will work faster. Lack of visible progress is a reason to reassess the diagnosis, formulation and expected outcome, not an automatic escalation trigger.

Injection volume is a separate constraint. At a hypothetical concentration of 1 mg/mL, 1 mg occupies 1 mL and 3 mg occupies 3 mL. Neither fits a 0.3–0.5 mL syringe as one draw. This corrects the earlier capacity contradiction; it is not advice to use a larger syringe, split injections or change concentration.

Reconstitution Guide: How to Prepare GHK-Cu for Injection

Correction: at 1 mg/mL, one U-100 unit marking corresponds to 0.01 mL and therefore 0.01 mg = 10 mcg, not 1 mg. The old FAQ overstated the amount per marking by a factor of 100. U-100 markings are volume references here, not biological units of GHK-Cu.

Arithmetic example, not a preparation recipe or dose recommendation: if a verified 5 mg amount were in a final solution volume of 5 mL, concentration would be 5 ÷ 5 = 1 mg/mL. At that concentration, 10 U-100 markings = 0.1 mL = 0.1 mg = 100 mcg; 100 markings = 1 mL = 1 mg. At 2 mg/mL the amount per marking doubles to 0.02 mg = 20 mcg. Do not carry markings from one concentration to another.

Actual preparation depends on the formulation, vial capacity, specified diluent, final volume and pharmacy instructions. Adding 5 mL to an unspecified vial is not a universal method. Bacteriostatic water is not automatically compatible with every drug, and the previous blanket prohibition on saline was not substantiated. The bacteriostatic-water label directs users to the drug manufacturer's compatibility, dilution and storage instructions.

Stability is formulation-specific. A topical preformulation study found chemical stability in the tested water and buffers, but degradation under particular oxidative/basic conditions and reduced stability with one lipid excipient. This is useful formulation evidence, not a sterile injectable shelf-life study. It does not validate the former generic 2–4-week refrigerator rule or weeks-to-months guarantee. Badenhorst, Svirskis and Wu.

Follow the dispensed product's storage and beyond-use instructions, including any handling limits after preparation. Appearance alone cannot establish sterility or potency. If identity, instructions, vial integrity or preparation history is uncertain, resolve that with the pharmacist rather than guessing a dilution or expiry.

Injection Technique & Administration

General injection education does not validate a GHK-Cu treatment. For an individually prescribed injectable preparation, the clinician or pharmacist should demonstrate the appropriate device and route. Do not substitute a fixed needle depth, warming period or internet site-selection rule for those instructions.

MedlinePlus describes subcutaneous injections as delivery into fatty tissue below the skin, with technique depending on the device and available tissue. Use a new sterile needle and syringe, healthy sites and appropriate sharps disposal. Increasing redness, pain, swelling or fever needs assessment; it is not evidence of collagen production.

There is no demonstrated reason in the reviewed human evidence to choose a site for localized collagen benefits or to rank the abdomen as having the best GHK-Cu absorption. The earlier lower-back recommendation and universal 0.5 cm depth were not a product-specific protocol.

Once-daily versus split dosing, morning versus evening, and injection near an injury have not been established by these topical studies. Scheduling symptoms to occur during sleep is not a substitute for evaluating them.

Cycling: How to Maintain Sensitivity & Prevent Tolerance

The former 8–12-week cycles and four-week breaks were presented as if they reset receptors. The evidence cited here does not establish that mechanism, a best cycle length, or that gains persist through a break. A study's observation period is not proof of a treatment cycle.

Continuing 0.5–1 mg during “off” weeks is still exposure, not a drug-free interval. Likewise, an indefinite maintenance schedule is not supported simply because short-term use was tolerated. There is no validated cycling schedule to recommend from the reviewed evidence.

If a clinician is overseeing treatment, agree on the intended outcome, reassessment point and reasons to stop. Emerging experience can inform the discussion, but should be described as experience rather than as a proven receptor-reset strategy.

Topical GHK-Cu: Concentration & Application

Topical GHK-Cu is studied in specific gels or skin-care regimens. Concentration alone does not describe delivery: the vehicle, amount applied, skin condition and frequency also matter. A percentage of a branded ingredient blend is not necessarily the percentage of pure GHK-Cu.

Emerging registered research: NCT07437586 lists a topical 0.1% w/w gel study in standardized wounds. The record checked September 9, 2026 is recruiting and has no posted results. It is a planned study regimen with dressings, not proof that 0.1% is optimal for every cosmetic use or that a retail serum treats an open wound.

For concentration literacy, 0.1% w/w means 1 mg per gram of finished product; 0.01% w/w means 0.1 mg per gram. It does not mean the same amount per mL without a density assumption, nor does it describe how much reaches tissue. Follow the particular product's application instructions rather than the previous universal two-to-three-pump rule.

The completed topical studies discussed above give reasons for further research, with mixed outcomes across settings. They do not establish that adding injections to a serum is superior, or a universal layering interval with retinoids, acids or other products. Product-specific irritation and compatibility still matter.

GHK-Cu Dosage for Specific Goals

Skin appearance: topical research is more directly relevant than a daily injection schedule. The laser-resurfacing trial's subjective benefit and objective null comparison should both be retained when setting expectations; it does not guarantee a particular cosmetic result in 8–12 weeks.

Hair: the reviewed evidence does not establish a human injection dose for hair regrowth or show that injections are essential and topical use insufficient. Hair loss has different causes. Claims of synergy with minoxidil or finasteride require evidence on the actual combination, not just evidence for each unrelated treatment.

Wounds and recovery: the diabetic-ulcer study evaluated a topical gel as part of structured wound care, not self-injection after surgery or an injury. It should not displace debridement, offloading, infection assessment or the treating team's care plan. Combining GHK-Cu with BPC-157 or TB-500 is not established as a faster-healing protocol by that trial.

Longevity: mechanisms involving tissue repair are not proof of longer human life. The sources reviewed do not establish an indefinite anti-aging dose or demonstrate that systemic exposure produces whole-body benefits.

Individual Response & Dose Adjustment

Reports of better skin, hair or recovery are worth distinguishing from controlled evidence, not dismissing. Their interpretation depends on route, product identity, concurrent treatments and how outcomes were measured. A report without those details cannot establish which amount caused the change.

If progress is slow: reassess the target problem and the evidence for the chosen approach. The former 0.5 mg increases every two weeks and a predicted response within 4–6 weeks were not substantiated.

If symptoms occur: do not automatically reduce the amount and assume the issue is resolved. Stop further exposure and seek advice for a suspected reaction; obtain prompt assessment for worsening local symptoms or systemic illness. Breathing difficulty or swelling of the face or throat warrants emergency care; see MedlinePlus on anaphylaxis. Mixing products or spacing injections 30 minutes apart has not been shown to prevent interactions.

Editorial correction, September 9, 2026: this update reconciles the U-100 arithmetic, syringe-capacity contradiction, route-specific evidence and unsupported cycle/storage claims. It is an editorial evidence review, not a claim of clinician review or validation of a personal treatment plan.

Want more GHK-Cu guidance? See our guides on GHK-Cu benefits, before and after results, and hair growth protocols.